Association Between Comorbidity and Clinical Trial Enrollment for Patients With Uterine Cancer

For patients with uterine cancer, comorbidity prevalence and comorbidity index scores varied by race. This results in differences in trial eligibility at baseline before any patient engagement. Quantifying the distribution of comorbidities is critical because it allows us to statistically anticipate how individual comorbidity eligibility criteria may hamper the accrual of patients from minoritized groups. This, in turn, can support equity efforts to plan trial eligibility criteria and targeted recruitment.